Volume 12, Number 8—August 2006
Dispatch
Changing Pattern of Visceral Leishmaniasis, United Kingdom, 1985-2004
Aeesha N.J. Malik*, Lawrence John*, Anthony D.M. Bryceson*, and Diana N.J. Lockwood*
Figure 2
Figure 2. Initial drug treatment for patients with visceral leishmaniasis and number of relapses. Na stibo, stibogluconate; Meg, meglumine antimoniate; Paro, paromomycin; Pent, pentamidine; Amb, ambisome; Amp, amphotericin.
Page created: December 09, 2011
Page updated: December 09, 2011
Page reviewed: December 09, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.